

CENTRAL FAX CENTER

JUL 25 2007



ProteoTech

Therapeutics for Human Disease  
Utilizing Proteoglycan Technologies

FACSIMILE COVER SHEET

ProteoTech Inc.  
12040 115<sup>th</sup> Ave. N.E.,  
Kirkland, WA 98034 U.S.A.

Phone: (425) 823-0400

FAX: (425) 823-8508

DATE: 24 July 2007TO: Examiner C. Tate  
USPTOFROM: ProteoTech, Inc.FAX: (571) 273-8300PHONE: (571) 272-0970Total Pages: 8 pages

Comments:

US Application No. 10/624,435

**CONFIDENTIALITY NOTICE:** This facsimile transmission is intended only for the use of the individual or entity to which it is addressed and may contain information belonging to the sender that is privileged, confidential or protected by law. All others are hereby notified that receipt of this message does not waive any applicable privilege or exemption from disclosure and that any dissemination, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this transmission in error, please notify this office by telephone or FAX to arrange for return of the documents. Thank you.

RECEIVED  
CENTRAL FAX CENTER

JUL 25 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Castillo et al.

Examiner: Tate, C.

Serial No.: 10/624,435

Group Art Unit: 1655

Filing Date: 07/21/2003

Attorney Docket: PROTEO.P18D2

Title of Invention: Methods of Isolating Amyloid-Inhibiting Compounds and Use of Compounds  
Isolated from Uncaria Tomentosa and Related Plants

Kirkland, Washington 98034

July 25, 2007

VIA FAX to:  
(571) 273-8300

RESPONSE TO OFFICE ACTION

Applicant acknowledges receipt of an Office Action dated July 11, 2007. Applicant  
responds to the Examiner's concerns as follows:

Certificate of Transmission (37 CFR 1.8a2iA)

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office (Fax No. (571) 273-8300) on July 25, 2007.

  
Karen Duncan